Literature DB >> 23347763

Ilizarov treatment of scaphoid nonunion.

Marko Bumbasirevic1, Henry D Atkinson2, Aleksandar Lesic3.   

Abstract

INTRODUCTION: This is single centre retrospective review of a consecutive series of patients with scaphoid nonunion (SNU) treated using the Ilizarov technique without bone graft. Fifteen of the original 18 patients were available for clinical and radiological examination at a minimum follow-up of 5 years (range 5-10 years). An evaluation was made of the late functional results, satisfaction scores, residual symptoms, grip strength and the presence of radiocarpal and scaphoid degenerative changes.
METHODS: The series consisted of 15 patients; 14 males; 1 female, with a mean SNU duration of 15.7 months, and a mean age of 23.6 years. Patients with carpal instability, humpback deformity, carpal collapse, avascular necrosis or marked degenerative change, were excluded from this treatment method. Following frame application the treatment consisted of three stages: distraction, compression and immobilisation. The technique is detailed herein.
RESULTS: Radiographic (CT) and clinical bony union was achieved in all 15 patients after a mean of 88 days (70-130 days). Mean modified Mayo wrist scores initially improved from 21 preoperatively to 86 at previous review, and were 96 at a mean follow-up of 81 months (62-120 months), with excellent results in 10, and good results seen in 5 patients. At latest review the mean grip strengths had returned to 96% of the uninjured hand, and 7 patients had regained full strength; mean wrist flexion/extension arc of motion had also continued to improve to 136° from 131°. All patients returned to their pre-injury occupations and levels of activity at a mean of 117 days. Three patients suffered superficial K-wire infections, which resolved with oral antibiotics. One patient continues to suffer intermittent mild aching in the wrist. No patient suffered loss of scaphoid height, humpback deformity, DISI instability or collapse of the regenerate bone.
CONCLUSION: In these selected patients this technique safely achieved bony union without the need to open the SNU site and without the need for bone graft. These patients also had the capacity to continually improve their wrist function beyond 3 years following their treatment.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23347763     DOI: 10.1016/j.injury.2013.01.016

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  6 in total

1.  Management of scaphoid nonunions with vascularized bone grafts from the distal radius: mid- to long-term follow-up.

Authors:  Konstantinos N Malizos; Zoe Dailiana; Sokratis Varitimidis; Antonios Koutalos
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-10-26

Review 2.  Non-vascularized bone grafting in scaphoid nonunion: principles and type of fixation.

Authors:  Ryoko Uesato; Satoshi Toh; Yoshimitsu Hayashi; Keiichiro Maniwa; Yasuyuki Ishibashi
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-10-19

3.  Ilizarov fixation for the treatment of scaphoid nonunion: a novel approach.

Authors:  Marko Bumbaširević; Tomislav Palibrk; Henry Dushan E Atkinson; Aleksandar Lešić
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-10-20

4.  Management of scaphoid nonunion with iliac crest bone graft and K-wire fixation.

Authors:  Erin Meisel; Alex Seal; Caroline A Yao; Alidad Ghiassi; Milan Stevanovic
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-11-09

5.  Pedicled vascularized bone grafts compared with xenografts in the treatment of scaphoid nonunion.

Authors:  S Matić; Č Vučković; A Lešić; I Glišović Jovanović; D Polojac; S Dučić; M Bumbaširević
Journal:  Int Orthop       Date:  2020-09-30       Impact factor: 3.075

6.  Modulation of Osteogenesis in MC3T3-E1 Cells by Different Frequency Electrical Stimulation.

Authors:  Yu Wang; Haitao Cui; Zhenxu Wu; Naipeng Wu; Zongliang Wang; Xuesi Chen; Yen Wei; Peibiao Zhang
Journal:  PLoS One       Date:  2016-05-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.